SPRUCE BIOSCIENCES, INC.
Qualité des données : 100%
SPRB
NASDAQ
Manufacturing
Chemicals
63,63 €
▼
2,38 €
(-3,61%)
Cap. Boursière: 87,30 M
Prix
63,63 €
Cap. Boursière
87,30 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—
Quick Summary
Points Clés
Debt/Equity of 0,10 — conservative balance sheet
Negative free cash flow of -33,33 M
Croissance
Revenue Growth (5Y)
N/A
Revenue (1Y)-100,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-419,76%
En dessous de la moyenne du secteur (-54,47%)
ROIC-293,65%
Net MarginN/A
Op. MarginN/A
Sécurité
Debt / Equity
0,10
En dessous de la moyenne du secteur (0,30)
Current Ratio1,54
Interest Coverage-405,70
Valorisation
PE (TTM|NTM)
-2,24 | -11,38
En dessous de la moyenne du secteur (-1,49)
P/B Ratio16,21
EV/EBITDAN/A
Dividend YieldN/A
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1385 pairs)
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1385 pairs)| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -2,2 | -1,5 |
| P/B | 16,2 | 1,6 |
| ROE % | -419,8 | -54,5 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,9 |
| D/E | 0,1 | 0,3 |
Objectif de Cours des Analystes
4 analystes
Buy
Actuel
63,63 €
Objectif
198,25 €
140,00 €
185,00 €
283,00 €
Prévisions
P/E Prévisionnel
-11,38
BPA Prévisionnel
-5,59 €
CA Est.
45,71 M
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2027 |
-5,59 €
-14,34 € – 11,69 €
|
45,71 M | 3 |
| FY2026 |
-27,43 €
-32,66 € – -20,25 €
|
0,0 | 3 |
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| 2026 Q2 |
-6,43 €
-8,20 € – -5,10 €
|
0,0 | 3 |
| 2026 Q1 |
-6,68 €
-8,92 € – -5,41 €
|
0,0 | 3 |
Surprises de Résultats
Derniers 4 trimestres
| Trimestre | BPA Est. | BPA Réel | Surprise |
|---|---|---|---|
| Q42025 | -9,57 € | -9,58 € | -0,2% |
| Q32025 | -12,31 € | -14,58 € | -18,4% |
| Q22025 | -18,00 € | -3,50 € | +80,6% |
| Q12025 | -19,50 € | -24,00 € | -23,1% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -100,00% | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0,0 | Net Income (TTM) | -38,97 M |
| ROE | -419,76% | ROA | -209,87% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -33,33 M |
| ROIC | -293,65% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,10 | Current Ratio | 1,54 |
| Interest Coverage | -405,70 | Asset Turnover | 0,00 |
| Working Capital | 5,09 M | Tangible Book Value | 5,39 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -2,24 | Forward P/E | -11,38 |
| P/B Ratio | 16,21 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 1,91 | Fwd Earnings Yield | N/A |
| FCF Yield | -38,17% | ||
| Market Cap | 87,30 M | Enterprise Value | 77,18 M |
| Per Share | |||
| EPS (Diluted TTM) | -50,83 | Revenue / Share | 0,00 |
| FCF / Share | -24,29 | OCF / Share | -24,29 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 85,53% |
| SBC-Adj. FCF | -35,35 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0,0 | 4,91 M | 10,09 M | — | — |
| Net Income | -38,97 M | -53,04 M | -47,92 M | -46,18 M | -42,29 M |
| EPS (Diluted) | -50,83 | -1,29 | -1,24 | -1,96 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -36,51 M | -56,15 M | -51,99 M | -47,28 M | -42,07 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 19,52 M | 46,42 M | 49,43 M | 35,20 M | 30,70 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 21 000,0 | 46 000,0 | 70 000,0 | 74 000,0 | 68 000,0 |
| Interest Expense | 90 000,0 | 307 000,0 | 483 000,0 | 420 000,0 | 345 000,0 |
| Income Tax | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 53,02 M | 45,21 M | 103,95 M | 85,65 M | 126,49 M |
| Total Liabilities | 10,51 M | 16,39 M | 27,44 M | 17,16 M | 15,12 M |
| Shareholders' Equity | 42,52 M | 28,82 M | 76,51 M | 68,49 M | 111,37 M |
| Total Debt | 0,0 | 1,84 M | 3,71 M | 5,64 M | 4,88 M |
| Cash & Equivalents | 48,91 M | 38,75 M | 96,34 M | 24,49 M | 42,75 M |
| Current Assets | 52,11 M | 44,21 M | 102,18 M | 83,61 M | 91,90 M |
| Current Liabilities | 10,09 M | 15,25 M | 24,47 M | 12,45 M | 8,87 M |
{"event":"ticker_viewed","properties":{"ticker":"SPRB","listing_kind":"stock","pathname":"/stocks/sprb","exchange":"NASDAQ","country":"US"}}